AR032677A1 - Compuestos triazolo como inhibidores de mmp - Google Patents
Compuestos triazolo como inhibidores de mmpInfo
- Publication number
- AR032677A1 AR032677A1 ARP020100471A ARP020100471A AR032677A1 AR 032677 A1 AR032677 A1 AR 032677A1 AR P020100471 A ARP020100471 A AR P020100471A AR P020100471 A ARP020100471 A AR P020100471A AR 032677 A1 AR032677 A1 AR 032677A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- group
- sulfur
- oxygen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto de quinazolina ciclada de formula (1) en donde: W representa N o C-R1; en donde R1 es como se define en la memoria; X representa N o C-R2; en donde R2 es como se define en la memoria; Y representa un grupo seleccionado de oxígeno, azufre, -NH y -N alquilo C1-6; Z representa un grupo seleccionado de: oxígeno, azufre y -NR8, en donde R8 es como se define en la memoria; n es un entero de 0 a 8 inclusive; Z1 representa un grupo -CR9R10, en donde R9 y R10, idénticos o diferentes, son como se definen en la memoria; A representa un grupo seleccionado de monociclo aromático o no aromático con 5 o 6 miembros, que abarca de 0 a 4 heteroátomos seleccionados de nitrogeno, oxígeno, y azufre; y biciclo, compuestos de dos anillos aromáticos o no aromáticos con 5 o 6 miembros, que pueden ser idénticos o diferentes, que abarcan de 0 a 4 heteroátomos seleccionados de nitrogeno, oxígeno y azufre; m es un entero de 0 a 7 inclusive; R4 puede ser idéntico o diferente, seleccionado de alquilo C1-6, halogeno, -CN, -NO2, -SCF3, -OCF3, -NR5R11, -OR5, -SR5, -SOR5, -SO2R5, -(CH2)kSO2NR5R11, -X1(CH2)kC(=O)OR5, -(CH2)kC(=O)OR5, -X1(CH2)kC(=O)R5R11, -(CH2)kC(=O)R5R11, y -X2-R12; en donde, X1, k, R5, R11, X2 y R12 son como se definen en la memoria; y R3 representa un grupo seleccionado de: hidrogeno, C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, los que pueden estar opcionalmente sustituidos por uno o más grupos tal como se define en la memoria; y el grupo de la formula (2) en donde, p, Z2, B, q y R13 son como se definen en la memoria. Proceso para la fabricacion del compuesto general de la formula (1) donde W, X, R3, R4, n, m, Z1 y A aparecen ya definidas , Y es O y Z es O, dicho proceso abarca la reaccion del compuesto de formula (3), en donde W, X, y R3 aparecen de acuerdo a lo definido en la formula (1), con el componente (4) para proporcionar el compuesto general de la formula (5) el cual es un caso particular de los compuestos de la formula (1). Composicion farmacéutica que comprende dicho compuesto y un excipiente aceptable. Uso de dicho compuesto para la preparacion de un producto medicinal creado para el tratamiento de una enfermedad o mal que incluye terapia por inhibicion de la matriz del tipo metaloproteasa-13. Dicho compuesto es de aplicacion para tratar artritis, artritis reumatoidea, osteoartritis, osteoporosis, enfermedades periodontales, enfermedades intestinales, psoriasis, esclerosis multiple, insuficiencia cardíaca, arteriosclerosis, asma, enfermedades pulmonares cronicas, degeneracion muscular originada por la edad y cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26875701P | 2001-02-14 | 2001-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR032677A1 true AR032677A1 (es) | 2003-11-19 |
Family
ID=23024335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020100471A AR032677A1 (es) | 2001-02-14 | 2002-02-13 | Compuestos triazolo como inhibidores de mmp |
Country Status (15)
Country | Link |
---|---|
US (1) | US6849637B2 (es) |
EP (1) | EP1362048B1 (es) |
JP (1) | JP2004521908A (es) |
AR (1) | AR032677A1 (es) |
AT (1) | ATE294805T1 (es) |
BR (1) | BR0207270A (es) |
CA (1) | CA2437588A1 (es) |
DE (1) | DE60203995T2 (es) |
ES (1) | ES2239216T3 (es) |
HN (1) | HN2002000038A (es) |
MX (1) | MXPA03007249A (es) |
PA (1) | PA8539501A1 (es) |
PE (1) | PE20020885A1 (es) |
SV (1) | SV2002000875A (es) |
WO (1) | WO2002064595A1 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
WO2002064598A1 (en) * | 2001-02-14 | 2002-08-22 | Warner-Lambert Company Llc | Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors |
US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
MXPA04002537A (es) | 2001-10-12 | 2004-05-31 | Warner Lambert Co | Alquinos como inhibidores de metaloproteinasa de matriz. |
US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
MXPA05000754A (es) * | 2002-07-17 | 2005-04-19 | Warner Lambert Co | Combinacion de un inhibidor carboxilico alosterico de la metaloproteinasa de matriz-13 con celecoxib o valdecoxib. |
MXPA05000729A (es) * | 2002-07-17 | 2005-04-08 | Warner Lambert Co | Combinacion de un inhibidor alosterico de metaloproteinasa-13 de matriz con celecoxib o valdecoxib. |
CA2489722A1 (en) * | 2002-07-17 | 2004-01-22 | William Howard Roark | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
AU2003281167A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
WO2004014365A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
WO2004014384A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
WO2004014378A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
WO2004014923A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
WO2004014867A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Matrix metalloproteinase inhibitors and methods for identification of lead compounds |
PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
MXPA05001785A (es) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de cromona como inhibidores de las metaloproteinasas de matriz. |
AU2003250471A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors |
MXPA05001784A (es) * | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de isoquinolina como inhibidores de metaloproteinasa de matriz. |
WO2004014375A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
WO2004014869A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
WO2004014908A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
AU2003253165A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
WO2004014909A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
AU2003253176A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Monocyclic derivatives as matrix metalloproteinase inhibitors |
BR0313724A (pt) | 2002-08-13 | 2005-06-28 | Warner Lambert Co | Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz |
US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
CA2572324A1 (en) * | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
AU2006251989B2 (en) * | 2005-05-20 | 2010-05-27 | Alantos-Pharmaceuticals, Inc. | Pyrimidine or triazine fused bicyclic metalloprotease inhibitors |
US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
US7795877B2 (en) * | 2006-11-02 | 2010-09-14 | Current Technologies, Llc | Power line communication and power distribution parameter measurement system and method |
CA2670083A1 (en) * | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
MY191407A (en) | 2008-01-04 | 2022-06-27 | Intellikine Llc | Certain chemical entities, compositions and methods |
DE102010031945A1 (de) * | 2010-07-22 | 2012-01-26 | Osram Opto Semiconductors Gmbh | Halbleiterbauelement und Verfahren zur Herstellung eines Halbleiterbauelements |
DK2663309T3 (en) | 2011-01-10 | 2017-06-19 | Infinity Pharmaceuticals Inc | METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2017223422A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
CN115197225B (zh) * | 2021-09-03 | 2023-04-11 | 贵州大学 | 一种五元杂环并喹唑啉酮类化合物及其制备方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4455311A (en) * | 1981-08-28 | 1984-06-19 | Hoffmann-La Roche Inc. | Imidazoquinazoline derivatives which inhibit the aggregation of blood platelets, inhibit gastric secretion or have activity on the circulatory system |
IL66835A (en) * | 1981-09-24 | 1988-05-31 | Roussel Uclaf | 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them |
EP0217748B1 (en) * | 1985-09-30 | 1991-02-06 | Ciba-Geigy Ag | 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof |
US6008243A (en) | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
IL128545A0 (en) | 1996-12-09 | 2000-01-31 | Warner Lambert Co | Method for treating and preventing heart failure and ventricular dilatation |
JPH11199512A (ja) | 1997-10-24 | 1999-07-27 | Pfizer Prod Inc | 変形性関節症および他のmmp媒介疾患の治療のためのmmp−13選択的阻害剤の使用 |
UA59453C2 (uk) | 1998-08-12 | 2003-09-15 | Пфайзер Продактс Інк. | Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ |
FR2792938B1 (fr) * | 1999-04-28 | 2001-07-06 | Warner Lambert Co | NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV |
HN2000000137A (es) | 1999-08-12 | 2001-02-02 | Pfizer Prod Inc | Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas |
US6934639B1 (en) | 2000-02-25 | 2005-08-23 | Wyeth | Methods for designing agents that interact with MMP-13 |
EP1138680A1 (en) | 2000-03-29 | 2001-10-04 | Pfizer Products Inc. | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors |
EA200300409A1 (ru) | 2000-10-26 | 2003-08-28 | Пфайзер Продактс Инк. | Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназы |
KR20040004412A (ko) | 2000-10-26 | 2004-01-13 | 화이자 프로덕츠 인크. | 스피로-피리미딘-2,4,6-트리온 메탈로프로테이나제 억제제 |
PA8539401A1 (es) | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
PA8539301A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
MXPA04002537A (es) | 2001-10-12 | 2004-05-31 | Warner Lambert Co | Alquinos como inhibidores de metaloproteinasa de matriz. |
JP2005509626A (ja) | 2001-10-12 | 2005-04-14 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテアーゼ−13阻害剤としてのアルキニル化縮合環ピリミジン化合物 |
US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
WO2003076416A1 (en) | 2002-03-08 | 2003-09-18 | Warner-Lambert Company Llc | Oxo azabicyclic compounds |
US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US20040006077A1 (en) | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
WO2004000321A1 (en) | 2002-06-25 | 2003-12-31 | Warner-Lambert Company Llc | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis |
WO2004014384A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
-
2002
- 2002-02-08 PA PA20028539501A patent/PA8539501A1/es unknown
- 2002-02-11 EP EP02702366A patent/EP1362048B1/en not_active Expired - Lifetime
- 2002-02-11 DE DE60203995T patent/DE60203995T2/de not_active Expired - Fee Related
- 2002-02-11 JP JP2002564526A patent/JP2004521908A/ja not_active Abandoned
- 2002-02-11 AT AT02702366T patent/ATE294805T1/de not_active IP Right Cessation
- 2002-02-11 ES ES02702366T patent/ES2239216T3/es not_active Expired - Lifetime
- 2002-02-11 CA CA002437588A patent/CA2437588A1/en not_active Abandoned
- 2002-02-11 BR BR0207270-0A patent/BR0207270A/pt not_active IP Right Cessation
- 2002-02-11 WO PCT/EP2002/001961 patent/WO2002064595A1/en active IP Right Grant
- 2002-02-11 MX MXPA03007249A patent/MXPA03007249A/es unknown
- 2002-02-13 SV SV2002000875A patent/SV2002000875A/es not_active Application Discontinuation
- 2002-02-13 AR ARP020100471A patent/AR032677A1/es not_active Application Discontinuation
- 2002-02-13 HN HN2002000038A patent/HN2002000038A/es unknown
- 2002-02-13 PE PE2002000115A patent/PE20020885A1/es not_active Application Discontinuation
- 2002-02-14 US US10/075,654 patent/US6849637B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6849637B2 (en) | 2005-02-01 |
BR0207270A (pt) | 2004-02-10 |
PA8539501A1 (es) | 2002-09-30 |
WO2002064595A1 (en) | 2002-08-22 |
PE20020885A1 (es) | 2002-10-26 |
ATE294805T1 (de) | 2005-05-15 |
EP1362048B1 (en) | 2005-05-04 |
JP2004521908A (ja) | 2004-07-22 |
MXPA03007249A (es) | 2005-02-14 |
EP1362048A1 (en) | 2003-11-19 |
HN2002000038A (es) | 2002-09-05 |
ES2239216T3 (es) | 2005-09-16 |
US20020151558A1 (en) | 2002-10-17 |
DE60203995D1 (de) | 2005-06-09 |
CA2437588A1 (en) | 2002-08-22 |
SV2002000875A (es) | 2002-10-04 |
DE60203995T2 (de) | 2005-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR032677A1 (es) | Compuestos triazolo como inhibidores de mmp | |
UY27173A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
CL2004000720A1 (es) | COMPUESTOS DERIVADOS DE PIRAZOLIDINA-1,2-DICARBOXILDIFENILAMIDA, INHIBIDORES DE LOS FACTORES DE COAGULACION Xa, VIIa; PROCESO DE PREPARACION; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; KIT FARMACEUTICO; Y SU USO PARA TRATAR TROMBOSIS, INFAR | |
PT1259512E (pt) | Compostos de pteridin para o tratamento da psoriase | |
CY1109728T1 (el) | Νεα παραγωγα υδαντοϊνης για τη θεραπεια αποφρακτικων νοσηματων της αναπνευστικης οδου | |
UY27882A1 (es) | Compuestos quimicos | |
UY28482A1 (es) | Nuevos compuestos | |
BR0307151A (pt) | Composto ou um sal do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso do composto ou de um seu sal, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente, como um ser humano, que necessita de um tratamento do tipo referido, e, processos para a preparação de 5-bromo-7- azaindol, e para a produção de 5-metóxi-7-azaindol | |
BR122013028005B8 (pt) | compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica, kit e forma de dosagem oral compreendendo os referidos compostos, uso das referidas composições, bem como processo de preparação dos referidos compostos | |
UY31215A1 (es) | Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia. | |
DE60315492D1 (de) | Medizinisch verwendbare arylethanolamin verbindungen | |
GB0223380D0 (en) | Combination therapy | |
DK1971338T3 (da) | Kombination af ZD6474 og pemetrexed | |
NO20072167L (no) | Kombinasjon omfattende ZD6474 og et antiandrogen | |
BRPI0411503A (pt) | composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto | |
NO20082566L (no) | Kombinasjon av AZ2171 og permetrexed | |
AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
ATE353650T1 (de) | Kombinationstherapie zur behandlung von krebs | |
NO20056171L (no) | Kombinasjonsterapi | |
NO20055754L (no) | Kolkisosidanaloger | |
MX2019006880A (es) | Inhibidores novedosos de glutaminil ciclasa y el uso de los mismos en el tratamiento de diversas enfermedades. | |
DE602005017590D1 (de) | Kombinationstherapie mit azd-2171 | |
EA201991188A1 (ru) | Новые ингибиторы глутаминилциклаз и их применение для лечения различных заболеваний | |
DE602004016754D1 (de) | Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839 | |
AR029415A1 (es) | Pirroles sustituidos, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |